Nevertheless, new studies suggest that CTLA4 blockade within the tumor microenvironment could decrease the activation threshold of T cells, while selectively depleting immunosuppressive regulatory T cells; these effects increase the number of tumor-specific CD8 T cells (4–6). The gene discussed is CD8A; the disease is neoplasm.